Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
RESEARCH TOOLSreports
Holding NMRA?
Track your performance easily
NMRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.33 - $21.00
Previous Close$11.91
Volume914.42K
Average Volume (3M)913.47K
Market Cap
$1.87B
Enterprise Value$1.51B
Total Cash (Recent Filing)£371.64M
Total Debt (Recent Filing)£3.61M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 12, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding160,027,746
10 Day Avg. Volume1,165,627
30 Day Avg. Volume913,466
Standard Deviation0.22
R-Squared0.38
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)5.34
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$24.17Price Target Upside90.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Neumora Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst reiterates the Outperform rating on NMRA, expressing confidence in a positive Phase 3 outcome across multiple studies.
Clinical TrialsA positive readout from the Ph 3 KOASTAL-1 study should drive significant upside in the stock price.
Market PotentialNavacaprant's novel KOR mechanism allows it to treat anhedonia, a significant unmet need in major depressive disorder, and it has a potential best-in-class safety and tolerability profile.
Bears Say
Clinical TrialsA clear miss in the KOASTAL-1 trial could send the stock down meaningfully as the market digests this and awaits the outcomes of both the second and third phase 3 studies.
Drug DevelopmentThe novelty of the KOR mechanism and uncertainty associated with placebo responses in major depressive disorder trials continue to weigh on the stock.
Investment RiskIt is difficult to continue to recommend adding to NMRA positions given the risk/reward skew at current levels, with roughly equal downside and upside barring best case results.
---
Ownership Overview
66.24% Insiders
6.79% Mutual Funds
2.45% Other Institutional Investors
19.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $8.33 and its highest was $21.00 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2024 which is in 5 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Aug 06, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.372 by $0.002.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -$0.39.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 160,027,740 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.372. Following the earnings report the stock price went up 0.251%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Among the largest hedge funds holding Neumora Therapeutics, Inc.’s share is Baker Bros Advisors LP. It holds Neumora Therapeutics, Inc.’s shares valued at 10M.
---
Neumora Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.17 (90.17% Upside)
$24.17 (90.17% Upside)
Blogger Sentiment
Bearish
NMRA Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 595.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 16.4%
Last 30 Days ▲ 16.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.50%
12-Months-Change
Fundamentals
Return on Equity
-77.08%
Trailing 12-Months
Asset Growth
12.37%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
---
NMRA Stock 12 Month Forecast
Average Price Target
$24.17
▲(90.17% Upside)
Technical Analysis
Best Analysts Covering NMRA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+8.31%
assigned a buy rating 2 months ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +8.31% per trade.
---